Evofem Biosciences, Inc. (EVFM) shareholders
EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026Market cap $42.93MP/E –Yield –
Ownership
Institutional holdings as of Dec 31, 2023, from 13F filings
Held by institutions
0.0%
0M of 133M shares
Institutional holders
0
0 new, 1 sold out
Net institutional buying
-0M
In Q4 2023
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| HUB Cyber Security Ltd. | 14,709,204 | 9.99% | 13D (active) | Jun 30, 2026 |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q4 2023 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q3 2023 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q3 2020 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q2 2020 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Yan Zhang CFO | Jan 12, 2024 | Sale | −104 | $0.04 | $4 | 0 |
| Kim P. Kamdar Director | Dec 21, 2023 | Sale | −10 | $0.62 | $6 | 0 |
| Justin J. File Chief Financial Officer | Dec 31, 2022 | Returned to company | −30,000 | – | – | 24,065 |
| Saundra L. Pelletier Chief Executive Officer, Director | Dec 31, 2022 | Returned to company | −50,000 | – | – | 186,722 |
| Saundra L. Pelletier Chief Executive Officer, Director | May 27, 2022 | Buy | +141,000 | $0.35 | $49.35K | 236,722 |
| Justin J. File Chief Financial Officer | Feb 18, 2022 | Award | +450,000 | – | – | 810,982 |
| Alexander A. Fitzpatrick General Counsel and Secretary | Feb 18, 2022 | Award | +300,000 | – | – | 516,422 |
| Saundra L. Pelletier Chief Executive Officer, Director | Feb 18, 2022 | Award | +750,000 | – | – | 1,435,837 |
| Justin J. File Chief Financial Officer | Dec 31, 2021 | Returned to company | −120,000 | – | – | 360,982 |
| Alexander A. Fitzpatrick General Counsel and Secretary | Dec 31, 2021 | Returned to company | −120,000 | – | – | 216,422 |
| Saundra L. Pelletier Chief Executive Officer, Director | Dec 31, 2021 | Returned to company | −300,000 | – | – | 685,837 |
| Alexander A. Fitzpatrick General Counsel and Secretary | Dec 20, 2021 | Buy | +25,000 | $0.39 | $9.75K | 336,422 |
| Saundra L. Pelletier Chief Executive Officer, Director | Dec 20, 2021 | Buy | +135,000 | $0.38 | $51.30K | 985,837 |
| Justin J. File Chief Financial Officer | Dec 20, 2021 | Buy | +40,594 | $0.37 | $15.02K | 480,982 |
| Russell Barrans Chief Commercial Officer | Jul 8, 2021 | Tax withholding | −19,998 | $0.98 | $19.60K | 448,554 |
| Kim P. Kamdar Director | Jun 18, 2021 | Buy | +10,000 | $1.17 | $11.70K | 19,287 |
| Anthony Stephen O'Brien Director | Jun 14, 2021 | Buy | +8,140 | $1.31 | $10.66K | 8,140 |
| Lisa Dale Rarick Director | Jun 11, 2021 | Buy | +5,000 | $1.20 | $6.00K | 10,250 |
| Russell Barrans Chief Commercial Officer | Jun 11, 2021 | Buy | +18,180 | $1.14 | $20.73K | 468,552 |
| Alexander A. Fitzpatrick General Counsel and Secretary | Jun 10, 2021 | Buy | +10,000 | $1.03 | $10.30K | 311,422 |
| Justin J. File Chief Financial Officer | Jun 10, 2021 | Buy | +24,500 | $1.03 | $25.24K | 440,388 |
| Saundra L. Pelletier Chief Executive Officer, Director | Jun 10, 2021 | Buy | +50,000 | $1.03 | $51.50K | 850,837 |
| Justin J. File Chief Financial Officer | May 20, 2021 | Tax withholding | −42,280 | $0.86 | $36.36K | 415,888 |
| Saundra L. Pelletier Chief Executive Officer, Director | May 20, 2021 | Tax withholding | −105,300 | $0.86 | $90.56K | 800,837 |
| Alexander A. Fitzpatrick General Counsel and Secretary | May 20, 2021 | Tax withholding | −42,120 | $0.86 | $36.22K | 301,422 |
| Kelly Culwell Chief Medical Officer | May 20, 2021 | Tax withholding | −42,061 | $0.86 | $36.17K | 273,390 |
| Russell Barrans Chief Commercial Officer | May 20, 2021 | Tax withholding | −31,480 | $0.86 | $27.07K | 450,372 |
| Saundra L. Pelletier Chief Executive Officer, Director | Mar 9, 2021 | Buy | +45,249 | $2.28 | $103.17K | 906,137 |
| Russell Barrans Chief Commercial Officer | Feb 3, 2021 | Award | +200,000 | – | – | 481,852 |
| Justin J. File Chief Financial Officer | Feb 3, 2021 | Award | +200,000 | – | – | 458,168 |
| Saundra L. Pelletier Chief Executive Officer, Director | Feb 3, 2021 | Award | +500,000 | – | – | 860,888 |
| Kelly Culwell Chief Medical Officer | Feb 3, 2021 | Award | +200,000 | – | – | 315,451 |
| Alexander A. Fitzpatrick General Counsel and Secretary | Feb 3, 2021 | Award | +200,000 | – | – | 343,542 |
| Justin J. File Chief Financial Officer | Nov 17, 2020 | Buy | +7,760 | $2.17 | $16.84K | 258,168 |
| Alexander A. Fitzpatrick General Counsel and Secretary | Nov 17, 2020 | Buy | +9,090 | $2.20 | $20.00K | 143,542 |
| Russell Barrans Chief Commercial Officer | Sep 11, 2020 | Buy | +3,000 | $2.08 | $6.24K | 279,052 |
| Russell Barrans Chief Commercial Officer | Sep 10, 2020 | Buy | +1,000 | $2.71 | $2.71K | 276,052 |
| Saundra L. Pelletier Chief Executive Officer, Director | Sep 8, 2020 | Sale | −122,500 | $3.26 | $399.35K | 360,888 |
| Russell Barrans Chief Commercial Officer | Jul 8, 2020 | Tax withholding | −20,381 | $3.30 | $67.26K | 275,052 |
| Lisa Dale Rarick Director | Jun 17, 2020 | Buy | +5,250 | $2.99 | $15.70K | 5,250 |
| William Walmsley Hall Director | Jun 15, 2020 | Buy | +5,000 | $2.85 | $14.25K | 5,000 |
| William Walmsley Hall Director | Jun 15, 2020 | Buy | +5,000 | $2.85 | $14.25K | 5,000 |
| Kim P. Kamdar Director, 10% owner | Jun 12, 2020 | Buy | +5,000 | $2.94 | $14.70K | 9,287 |
| Justin J. File Chief Financial Officer | Jun 12, 2020 | Buy | +8,500 | $3.14 | $26.69K | 250,408 |
| Ltd. Invesco 10% owner | Jun 5, 2020 | Buy | +857,143 | $3.50 | $3.00M | 13,226,532 |
| Russell Barrans Chief Commercial Officer | Jun 5, 2020 | Tax withholding | −15,455 | $3.31 | $51.16K | 293,509 |
| Kelly Culwell Chief Medical Officer | Jun 5, 2020 | Tax withholding | −31,548 | $3.31 | $104.42K | 115,451 |
| Alexander A. Fitzpatrick General Counsel and Secretary | Jun 5, 2020 | Tax withholding | −31,590 | $3.31 | $104.56K | 134,452 |
| Saundra L. Pelletier Chief Executive Officer, Director | Jun 5, 2020 | Tax withholding | −85,620 | $3.31 | $283.40K | 479,085 |
| Justin J. File Chief Financial Officer | Jun 5, 2020 | Tax withholding | −42,810 | $3.31 | $141.70K | 237,605 |
| Fund Solutions Ltd Link 10% owner | Jun 4, 2020 | Sale | −9,138,504 | $0.23 | $2.10M | 0 |
| Research Corp Acacia 10% owner | Jun 4, 2020 | Sale | −9,138,504 | $3.21 | $29.33M | 1,000 |
| Ltd. Invesco 10% owner | May 26, 2020 | Sale | −65 | $5.98 | $389 | 12,369,389 |
| Ltd. Invesco 10% owner | May 26, 2020 | Sale | −73,814 | $5.79 | $427.38K | 12,369,454 |
| Russell Barrans Chief Commercial Officer | May 22, 2020 | Tax withholding | −19,474 | $4.99 | $97.18K | 308,964 |
| Kelly Culwell Chief Medical Officer | May 22, 2020 | Tax withholding | −39,435 | $4.99 | $196.78K | 146,999 |
| Alexander A. Fitzpatrick General Counsel and Secretary | May 22, 2020 | Tax withholding | −39,487 | $4.99 | $197.04K | 166,042 |
| Justin J. File Chief Financial Officer | May 22, 2020 | Tax withholding | −42,262 | $4.99 | $210.89K | 280,415 |
| Saundra L. Pelletier Chief Executive Officer, Director | May 22, 2020 | Tax withholding | −84,525 | $4.99 | $421.78K | 564,705 |
| Pdl Biopharma, Inc. 10% owner | May 21, 2020 | Other | −13,333,334 | – | – | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+134.6%
From 0M shares
Short volume, 20 days
50.5%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Evofem Biosciences's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
See a number that looks wrong?